GC Biopharma Corp. · KRX:006280
GC Biopharma — Investor Day (January 2024)
14 slides from GC Biopharma's investor day presentation, Jan 31, 2024
Slide 1: R&D Update
<> GCBiopharma | R&D update @ R80 Strategy @ Rare Diseases @ mRNA platform
Slide 2: R&D Strategy: Strengthening Current Three Main Pillars
03. R&D Strategy: STRENGTHENING CURRENT THREE MAIN PILLARS Expanding into Global market, Enhancing Technology and Value of Existing Products, Continuously Expanding our Portfolio > GCBiopharma gets ~ Curr 24 & Be + Launching Green Gene F, the treatment for + Completion of Phase 1 clinical study of M
Slide 3: R&D Strategy: Adding Another Key Pillar as a Potential Big Growth
03. R&D Strategy: ADDING ANOTHER KEY PILLAR AS A POTENTIAL BIG GROWTH Establishing and Expanding Disease Research Centered on Immunology > Building an mMRNA/LNP Platform and Securing Technological Competency > GCBiopharma 01 Intersection with the rare disease treatment development track’) 02. Immuno
Slide 4: Advantage of mRNA/LNP Platform: Sample Preparation and Development Time
03. > GCBiopharma Advantage of mRNA/LNP PLATFORM: Sample Preparation and Development Time + For small molecules, lead optimization takes approximately 3 to 5 years on average + For general antibodies, the stages from cell line development to clinical sample production takes approximately 10 to 17 mo
Slide 5: Growth in mRNA Vaccines and Treatments
03. > GCBiopharma Growth in mRNA Vaccines and Treatments + The mRNA based pharmaceutical market is anticipated to reach USD 68 billion by 2030 + In addition to COVID-19 vaccines, various other vaccines and disease treatments are under clinical development Major Development Trend Market Size of Globa
Slide 6: R&D Investment: Continuous Investment in New Platforms Fuels Growth
03. R&D update R&D Investment : Continuous Investment in New Platforms Fuels Growth in New Projects R&D Investment Allocation by Area (Units: KRW billion) +9°%0 —~ 128.0 135.1 New platform-based projects (mRNA/LNP platform and related projects) Current platform-based projects (recombinant proteins,
Slide 7: Pipeline (as of January 2024)
03. R&D PIPELINE (as of January 2024) > GCBiopharma Pre al >> Phase l >> Phase Il >> = Phase III ation/Approved GC5125 GC5107D US GC5107B US Plasma. vWF Deficiency Primary Immune Primary Immune erivative (FDA pre-IND meeting) Deficiency(Pediatric) Deficiency Gc4002 MG1120/CRV-101 Global MG1111 KR In
Slide 8: Pipeline (goals to achieve by December 2024)
03. R&D PIPELINE (goals to achieve by December 2024) Plasma Derivative Vaccine Innovative medicine Prec al GC5125 vWF Deficiency (FDA pre-IND meeting) Gc4002 Influenza(mRNA) Gc3111 Tdap Gc4003 SSADH Deficiency(mRNA\ GC2126A Gangliosidosis YR >> Phase! GC3111 KR Tdap MG1113 KR Hemophilia A/B GC1123 K
Slide 9: GC1130: Mucopolysaccharidosis IIIA
03. GC1130: Mucopolysaccharidosis IIIA > GCBiopharma Co-Developer NOVEL @=“PHARMA Market Forecast GC1130 Achievements in 2023 and Plans for 2024 A disease with neurological degeneration Strategy | Direct admission of treatment US FDA ODD2), RPDD?) Approval starting around the age of three, leading t
Slide 10: CSF-14day brain-14day
✱✱✱✱ ✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱ ✱✱ ✱✱✱✱ ✱✱ ✱ 20 2000 1500 15 CSF-14day brain-14day 1000 10 500 5 0 0 e e g g g e ne g g g lin lin 12 u 7u 0u alin li 12 u 7u 0u -sa sa A A3 11 -s sa A A3 11 WT 30 11 30 30 A WT 30 3 0 30 A 11 11 11 11 11 GC GC GC GC GC GC
Slide 11: Fabry mice model, GC1134 1.6mg/kg = 1.0mg/kg as GLA
○ Agalsidase(iv) 1.0 mg/kg ○ GC1134(iv) 1.6 mg/kg ● GC1134(sc) 1.6 mg/kg abry mice model, GC1134 1.6mg/kg = 1.0mg/kg as GLA
Slide 12: mRNA/LNP Platform Strategy and Research Directions
03. > GCBiopharma mRNA/LNP Platform Strategy and Research Directions | Completed by 2023 | by 2023 | ongoing] Aim to secure intellectual property”) and achieve global-level competency Increased Utility mRNA Internal project Build-Up + Completed 1st stage development of A.! based codon * Quadrivalent
Slide 13: [Back-up] GC4003: Succinic semialdehyde dehydrogenase deficiency
03. a }GCBiopharma [Back-up] GC4003: Succinic semialdehyde dehydrogenase deficiency Recombinant protein mRNA prototype/LNP (2023.05) Optimized MRNA/LNP (2023.08) + Protein undetected after 2hours + Verified maintenance of protein + Verified maintenance of protein expression on day7 expression on day
Slide 14: Milestone
03. R&D MILESTONE Achievements in 2023 © 01 Obtained US FDA License for IGIV 02 Lifted Conditional License Approval of Hunterase 03 Obtained Approval of Livmarli for the treatment of Alagille syndrome 04 Completed Phase 2 Clinical Study for Varicella Vaccine 05 MPSIIIA Treatment Designated as US ODD